HTMC0658

Phase 2Small molecule

SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.

HTMC0658 is one of 4 small molecule programs targeting Chronic Rhinosinusitis Without Nasal Polyps. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Rhinosinusitis Without Nasal PolypsRecruiting

Chronic Rhinosinusitis Without Nasal PolypsPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Chronic Rhinosinusitis Without Nasal Polyps

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Approved

3 2

Asmanex Hfa

PPerrigo Company

Approved

1 3

HTMC0658

SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Phase 2

1 4

Augmentin

Teva

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Rhinosinusitis Without Nasal Polyps1 trial

A Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps

Recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07174115·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HTMC0658. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HTMC0658 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HTMC0658. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.

HTMC0658

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Rhinosinusitis Without Nasal Polyps1 trial

References

Drug Info

Quick Facts

Related News